



House of Commons

NOTICES OF AMENDMENTS

given up to and including
Friday 11 December 2015

New Amendments handed in are marked thus ★

☆ *Amendments which will comply with the required notice period at their next appearance*

Amendments tabled since the last publication: 1-9, NC1-NC2

PUBLIC BILL COMMITTEE

ACCESS TO MEDICAL TREATMENTS (INNOVATIONS) BILL

NOTE

This document includes all amendments tabled to date, arranged in the order they relate to the Bill.

Justin Madders

1

★ Clause 1, page 1, line 3, leave out from “to” to “for” in line 5 and insert “provide”

Nick Thomas-Symonds

7

★ Clause 1, page 1, line 3, after “treatments” insert, “, including access to off-patent drugs in new indications,”

Justin Madders

2

★ Clause 1, page 1, leave out lines 8 and 9

Access to Medical Treatments (Innovations) Bill, continued

Nick Thomas-Symonds

8

★ Clause 1, page 1, line 9, at end insert—

- “(c) providing for the establishment of an arm’s length body to provide assistance to those seeking regulatory approval for off-patent drugs in new indications.”
-

Justin Madders

3

★ Clause 2, page 1, leave out line 17 and insert—

- “(b) all of the positive and negative results of such treatments, and”

Justin Madders

4

★ Clause 2, page 1, line 17, at end insert—

- “(c) patient experiences of such treatments.”

Nick Thomas-Symonds

9

★ Clause 2, page 1, line 29, after “involves” insert—

- “(a) the use of off-patent drugs in new indications where there is strong evidence for their effectiveness; and
 (b) a departure from the existing range of accepted medical treatments for the condition”.

Justin Madders

5

★ Clause 2, page 2, line 20, at end insert—

- “(b) the General Medical Council,
 (c) the British Medical Association,
 (d) the Association of Medical Research Charities,
 (e) the Royal Colleges,
 (f) the Academy of Medical Sciences,
 (g) the Medical Research Council,
 (h) the National Institute for Health and Care Excellence, and
 (i) the Medicines and Health Products Regulatory Agency.”

Justin Madders

6

★ Clause 2, page 2, line 20, at end insert—

- “(6A) Regulations under subsection (1) may not be made unless the Secretary of State is satisfied that the regulations have the approval in principle of—

- (a) the HSCIC,
 (b) the General Medical Council,
 (c) the British Medical Association,
 (d) the Association of Medical Research Charities,
 (e) the Royal Colleges,

Access to Medical Treatments (Innovations) Bill, continued

- (f) the Academy of Medical Sciences,
 - (g) the Medical Research Council,
 - (h) the National Institute for Health and Care Excellence, and
 - (i) the Medicines and Health Products Regulatory Agency.”
-

NEW CLAUSES

Nick Thomas-Symonds

NC1

- ★ To move the following Clause—

“Licenses for off-patent drugs

- “() The Secretary of State, or a body nominated by the Secretary of State, has a duty to seek licences for off-patent drugs in new indications where—
 - (a) there is no commercial incentive for a profit-making body to do so,
 - (b) there is robust evidence of its effectiveness in the new indication, and
 - (c) the drug meets NICE’s prioritisation criteria for Technology Appraisals.”
-

Nick Thomas-Symonds

NC2

- ★ To move the following Clause—

“Appraisals for off-patent drugs

- “() The Secretary of State has a duty to direct NICE technology appraisals or a suitable alternative, for off-patent drugs in new indications where—
 - (a) there is no commercial incentive for a profit-making body to do so,
 - (b) there is robust evidence of its effectiveness in the new indication, and
 - (c) the drug meets NICE’s prioritisation criteria for Technology Appraisals.”
-